Bruton’s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bruton’s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma

Published:2014-11-30 Issue:2 Volume:466 Page:229-235
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Fernández-Vega Iván,Quirós Luis M.,Santos-Juanes Jorge,Pane-Foix María,Marafioti Teresa

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00428-014-1698-z.pdf

Reference27 articles.

1. Bao Y, Zheng J, Han C, Jin J, Han H, Liu Y, Lau YL, Tu W, Cao X (2012) Tyrosine kinase Btk is required for NK cell activation. J Biol Chem 287:23769–23778. doi: 10.1074/jbc.M112.372425

2. Block H, Zarbock A (2012) The role of the tec kinase Bruton’s tyrosine kinase (Btk) in leukocyte recruitment. Int Rev Immunol 31:104–118. doi: 10.3109/08830185.2012.668982

3. Braeuninger A, Kuppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML (1997) Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A 94:9337–9342

4. Brunner C, Muller B, Wirth T (2005) Bruton’s tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol 20:945–955

5. Buggy JJ, Elias L (2012) Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 31:119–132. doi: 10.3109/08830185.2012.664797

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Ibrutinib Combined with Compound Realgar Natural Indigo Tablets for the Treatment of Relapsed and Refractory Hodgkin Lymphoma: A Case Report and Literature Review;Advances in Clinical Medicine;2024

3. A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma;Cancers;2023-02-24

4. Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group;Hematological Oncology;2022-03-24

5. Clinicopathologic and Prognostic Significance of Bruton’s Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma;Anticancer Research;2021-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3